Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lannett Looks To Transform Company With Five Pipeline Assets

As Company Reports Another Low Financial Quarter

Aug 27 2021

• By Akriti Seth

strategy — Lannett expects five approvals by 2025 • Source: Alamy

Related Content

Lannett Files ANDA For US Advair Rival

Apr 01 2021

Lannett On Track To Launch Insulin Glargine By 2023

Mar 11 2021

Related Companies

Lannett Company, Inc.

Additional Topics

Biosimilars Generic Drugs Launches Sales & Earnings Strategy BioPharmaceutical

More from Biosimilars

More from Products

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.